Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H25NO3.ClH |
| Molecular Weight | 375.889 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=C(C=C1)[C@H]([C@@H](CN(C)CC(O)=O)CC2)C3=CC=CC=C3
InChI
InChIKey=SDTLOODMXMDJFX-JKSHRDEXSA-N
InChI=1S/C21H25NO3.ClH/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15;/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24);1H/t17-,21+;/m1./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H25NO3 |
| Molecular Weight | 339.4281 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/25257291Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24525661 |
https://www.ncbi.nlm.nih.gov/pubmed/22394471
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25257291
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24525661 |
https://www.ncbi.nlm.nih.gov/pubmed/22394471
Org 25935 (SCH 900435) is a synthetic drug developed by Organon International, which acts as a selective inhibitor of the glycine transporter GlyT-1. In human trial for prevention of relapse in alcohol-dependent patients in Org 25935 demonstrated no benefit over placebo in preventing alcohol relapse. Org 25935 was tested as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia, where it did not differ significantly from placebo in reducing negative symptoms or improving cognitive functioning. Clinical trials against panic disorder did not show any benefit compared to placebo.
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
72 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748 |
4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ORG-25935 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
243 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748 |
16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ORG-25935 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
159 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748 |
8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ORG-25935 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
165 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748 |
12 mg 2 times / day multiple, oral dose: 12 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ORG-25935 plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Efficacy and safety of the glycine transporter-1 inhibitor org 25935 for the prevention of relapse in alcohol-dependent patients: a randomized, double-blind, placebo-controlled trial. | 2014-09 |
|
| The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. | 2014-04 |
|
| Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial. | 2012-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24525661
In clinical trial against schizophrenia Org 25935 was tested at 4 to 8 mg twice daily and 12 to 16 mg twice daily.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:04:44 GMT 2025
by
admin
on
Mon Mar 31 18:04:44 GMT 2025
|
| Record UNII |
H6MSM69SSM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1146978-08-6
Created by
admin on Mon Mar 31 18:04:44 GMT 2025 , Edited by admin on Mon Mar 31 18:04:44 GMT 2025
|
PRIMARY | |||
|
11740218
Created by
admin on Mon Mar 31 18:04:44 GMT 2025 , Edited by admin on Mon Mar 31 18:04:44 GMT 2025
|
PRIMARY | |||
|
DBSALT002157
Created by
admin on Mon Mar 31 18:04:44 GMT 2025 , Edited by admin on Mon Mar 31 18:04:44 GMT 2025
|
PRIMARY | |||
|
DTXSID701029795
Created by
admin on Mon Mar 31 18:04:44 GMT 2025 , Edited by admin on Mon Mar 31 18:04:44 GMT 2025
|
PRIMARY | |||
|
949588-40-3
Created by
admin on Mon Mar 31 18:04:44 GMT 2025 , Edited by admin on Mon Mar 31 18:04:44 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
H6MSM69SSM
Created by
admin on Mon Mar 31 18:04:44 GMT 2025 , Edited by admin on Mon Mar 31 18:04:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |